Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.58 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891556 | 0.85 | GRM5 (0.58) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL2738120 | 0.85 | GRM5 (0.45) | GRM5PDK4ESR2NAMPTGPR119 | |
| SCHEMBL2893138 | 0.84 | GRM5 (0.63) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL20001581 | 0.81 | GRM5 (0.60) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL3348910 | 0.81 | GRM5 (0.66) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL743098 | 0.80 | GRM5 (0.58) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL15991177 | 0.80 | GRM5 (0.58) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL941018 | 0.79 | GRM5 (0.61) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL13804065 | 0.79 | PDK4 (0.49) | GRM5PDK4GRM1ESR2NAMPT | |
| SCHEMBL3997777 | 0.79 | GRM5 (0.49) | GRM5PDK4GRM1ESR2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2758377-B1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2758377-B1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9493441-B2 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493441-B2 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493441-B2 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140228358-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228358-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| WO-2013127808-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013043962-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228358-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | GRM5 2373/4885PDK4 1307/4885GRM1 1699/4885 |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | GRM5 2325/4885PDK4 1285/4885GRM1 1491/4885 |
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | GRM5 26/4885PDK4 638/4885GRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.